1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 6.843 ml | 34.214 ml | 68.428 ml |
5 mM | 1.369 ml | 6.843 ml | 13.686 ml |
10 mM | 0.684 ml | 3.421 ml | 6.843 ml |
50 mM | 0.137 ml | 0.684 ml | 1.369 ml |
- 提示:詳情請下載說明書。
- 產品描述: VAL-083 is an alkylating agent that creates N7 methylation on DNA, with antitumor activity.
- 靶點: DNA Alkylator;DNAAlkylator/Crosslinker;?DNAAlkylation
- 體內研究:
VAL-083 (Dianhydrogalactitol; 25, 50, 100 μg/mL) dose-dependently inhibits angiogenesis in zebrafish model. VAL-083 considerably reduces VEGF, VEGFR2, and FGF2 expression at 25 μg/mL, and further causes reduction in FGFR2 expression at 50 μg/mL. VAL-083 (1,2:5,6-dianhydrogalactitol; 5 mg/kg, iv, twice per week for 6 weeks) significantly blocks the growth of LN229 cells in mice with the relative tumor growth rate (T/C) of 22.38%, and the tumor growth inhibitory rate (TGI) of 83.58%. Moreover, VAL-083 dramatically activates the CDC25C-CDK1 cascade in the xenografted tumor moedl
- 參考文獻:
1. Kaiji Hu, et al. Abstract 811: VAL083, a novel N7 alkylating agent, surpasses NSC 362856 activity and inhibits cancer stem cells providing a new potential treatment option for glioblastoma multiforme. Cancer Research. 2012 Mar 31-Apr 4. 2. Jiang X, et al. Dianhydrogalactitol, a potential multitarget agent, inhibits glioblastoma migration, invasion, and angiogenesis. Biomed Pharmacother. 2017 Jul;91:1065-1074. 3. Peng C, et al. 1,2:5,6-dianhydrogalactitol inhibits human glioma cell growth in vivo and in vitro by arresting the cell cycle at G2/M phase. Acta Pharmacol Sin. 2017 Apr;38(4):561-570.
- 溶解性: DMSO : 200 mg/mL (1368.55 mM; ultrasonic and warming and heat to 60°C) DMF : ≥ 100 mg/mL (684.28 mM) H2O : 50 mg/mL (342.14 mM; Need ultrasonic)
- 保存條件: -20℃
- 配置溶液濃度參考:
1mg 5mg 10mg 1 mM 6.843 ml 34.214 ml 68.428 ml 5 mM 1.369 ml 6.843 ml 13.686 ml 10 mM 0.684 ml 3.421 ml 6.843 ml 50 mM 0.137 ml 0.684 ml 1.369 ml
- 注意:部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。
輸入產品批號:
本計算器可幫助您計算出特定溶液中溶質的質量、溶液濃度和體積之間的關系,公式為:
質量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)